Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
- D Luftner (Author)
- R Bartsch (Author)
- U Breitenstein (Author)
- Balic, M. (Author)
- C Jackisch (Author)
- V Muller (Author)
- G Rinnerthaler (Author)
- M Schmidt (Author)
- M Schwitter (Author)
- K Zaman (Author)
- D Wrobel (Author)
- D Guth (Author)
- J Terhaag (Author)
- M Zaiss (Author)
- A Distelrath (Author)
- A Lorenz (Author)
- T Schinkothe (Author)
- N Harbeck (Author)
Activity: Talk, presentation or poster › Poster